Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Parkinson's Disease

  Free Subscription


08.09.2025

1 Biochemistry (Mosc)
1 Brain Res
3 J Biol Chem
3 J Neural Transm (Vienna)
1 J Neurochem
5 Mov Disord
1 Nat Med
3 Neurobiol Dis
1 Neurologia (Engl Ed)
2 Neurology
1 Neuroscience


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Biochemistry (Mosc)

  1. PCHELINA SN, Bezrukova AI, Rudenok MM, Zhuravlev AS, et al
    The Double Toxic MPTP+CBE Presymptomatic Parkinson-Like Phenotype in Mice.
    Biochemistry (Mosc). 2025;90:1049-1063.
    PubMed         Abstract available


    Brain Res

  2. CAI L, Ding Y, Tekreeti AA, Li F, et al
    Remote ischemic conditioning as a potential therapy for Parkinson's Disease: Inhibiting TLR4-Driven neuroinflammation and oxidative damage.
    Brain Res. 2025 Sep 1:149920. doi: 10.1016/j.brainres.2025.149920.
    PubMed         Abstract available


    J Biol Chem

  3. ADHIKARI A, Tripathi A, Chiang CY, Sherpa P, et al
    Allosteric regulation of the Golgi-localized PPM1H phosphatase by Rab GTPases modulates LRRK2 substrate dephosphorylation in Parkinson's disease.
    J Biol Chem. 2025 Sep 3:110679. doi: 10.1016/j.jbc.2025.110679.
    PubMed         Abstract available

  4. SAWAI T, Nakamura Y, Arawaka S
    Secretory autophagy mediates lysosomal and autophagic degradation for alpha-synuclein proteostasis.
    J Biol Chem. 2025;301:110474.
    PubMed         Abstract available

  5. SHEN L, Zhang J, Wang Z, Liu Y, et al
    Targeted degradation of alpha-synuclein by arginine-based PROTACs.
    J Biol Chem. 2025;301:110449.
    PubMed         Abstract available


    J Neural Transm (Vienna)

  6. REYES NGD, Pajo AT, Saranza G, Hoglinger GU, et al
    Revisiting Parkinson's disease definition and classification: insights from two emerging biological frameworks.
    J Neural Transm (Vienna). 2025 Sep 4. doi: 10.1007/s00702-025-03013.
    PubMed         Abstract available

  7. JENNER P, Nyholm D
    COMT inhibition with entacapone for patients with Parkinson's disease and motor complications: the novelty of continuous infusion.
    J Neural Transm (Vienna). 2025 Sep 2. doi: 10.1007/s00702-025-03006.
    PubMed         Abstract available

  8. PELLICANO C, Belvisi D, Bovenzi R, Costanzo M, et al
    Opicapone in Parkinson's disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit.
    J Neural Transm (Vienna). 2025 Aug 31. doi: 10.1007/s00702-025-03000.
    PubMed         Abstract available


    J Neurochem

  9. USENKO TS, Basharova KS, Bezrukova AI, Grigor'eva EV, et al
    Restoration of Lysosomal Hydrolase Activities by LRRK2 Inhibition in GBA1- and LRRK2-Associated Parkinson's Disease Patient-Derived Cells.
    J Neurochem. 2025;169:e70214.
    PubMed         Abstract available


    Mov Disord

  10. FANT A, Trova S, Monfrini E, Treves G, et al
    Compound Heterozygous Structural Variants in Cases with Unsolved PRKN-Associated Parkinson's Disease.
    Mov Disord. 2025 Aug 30. doi: 10.1002/mds.70027.
    PubMed         Abstract available

  11. HAQ IU, Simonyan K, Napoli E, Ozelius LJ, et al
    Structural Alterations in the Gray Matter Volume in Rapid-Onset Dystonia-Parkinsonism.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.30320.
    PubMed         Abstract available

  12. SCHIESS MC, Suescun J, Martinez-Lemus JD, Green C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.70028.
    PubMed         Abstract available

  13. DE MORAES ALVES AL, da Silva Simoes J, Trajano da Silva LR, Neto AF, et al
    Transcutaneous Spinal Magnetic Stimulation Affects Subthalamic Activity in Parkinson's Disease.
    Mov Disord. 2025 Sep 3. doi: 10.1002/mds.70035.
    PubMed        

  14. AL-AZZANI M, Weber S, Ramalingam N, Ramon M, et al
    A Novel alpha-Synuclein K58N Missense Variant in a Patient with Parkinson's Disease.
    Mov Disord. 2025 Sep 4. doi: 10.1002/mds.70030.
    PubMed         Abstract available


    Nat Med

  15. ALI M, Erabadda B, Chen Y, Xu Y, et al
    Author Correction: Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.
    Nat Med. 2025 Sep 2. doi: 10.1038/s41591-025-03970.
    PubMed        


    Neurobiol Dis

  16. LI P, Zhou X, Luo N, Zhou S, et al
    Dynamic cortical inhibition imbalance as a biomarker of clinical progression in early Parkinson's disease.
    Neurobiol Dis. 2025 Sep 3:107083. doi: 10.1016/j.nbd.2025.107083.
    PubMed         Abstract available

  17. BHARTI E, DeNicola AL, Yu Y, Verma AK, et al
    Alterations in beta oscillatory activity occur with the emergence of parkinsonian motor signs across the basal ganglia-thalamocortical network.
    Neurobiol Dis. 2025;215:107075.
    PubMed         Abstract available

  18. CHEN T, Gong T, Chen Y, Yang A, et al
    Multimodal MRI biomarkers optimize differentiation between progressive supranuclear palsy and Parkinson's disease.
    Neurobiol Dis. 2025;215:107076.
    PubMed         Abstract available


    Neurologia (Engl Ed)

  19. MURUETA-GOYENA A, Del Pino R, Carmona-Abellan M, Tijero B, et al
    Effect of sex on the progression of non-motor symptoms in Parkinson's disease: A registry-based cohort study.
    Neurologia (Engl Ed). 2025;40:620-629.
    PubMed         Abstract available


    Neurology

  20. AITA SL, Roth RM
    Much Ado About Nothing? Midlife Vascular Risk Factors and Incident Parkinson Disease.
    Neurology. 2025;105:e214127.
    PubMed        

  21. JOHRI M, Morrill V, Okine DN, Huang X, et al
    Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia: The ARIC Study.
    Neurology. 2025;105:e213931.
    PubMed         Abstract available


    Neuroscience

  22. ZHIDAN L, Xianjie L, Shulin S, Qiang J, et al
    TREM2 mediates parkinsonism-like neurodegeneration in carbon disulfide-induced neurotoxicity.
    Neuroscience. 2025;585:50-59.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.